Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka? Japan; President & Representative Director: Hiroaki Ueno) announced that MTPC concluded a drug discovery research collaboration with HitGen Inc. (Head Office: Chengdu, China; Chairman & CEO: Jin Li) for the discovery of seed compounds for drug discovery target molecules in December 2018, and the agreement expired in December 2021.

In the three-year collaborative research, several drug discovery target molecules were screened against HitGen's original next-generation compound library (DNA encoded chemical libraries: DELs), comprising more than 1 trillion compounds. We were able to obtain seed compounds for several target molecules. MTPC will create hit compounds and lead compounds through compound development. As part of MTPC?s growth strategy to realize 'VISION 30', which was formulated as MTPC?s company vision for 2030, MTPC is focusing on 'Precision Medicine', MTPC is advancing drug discovery research with the goal of creating breakthrough drugs. MTPC will continue to take on the challenge of creating innovative drugs that meet unmet medical needs through open innovation with various partners.

Contact:

Media

TEL: +81 6 6205 5119

(C) 2022 Electronic News Publishing, source ENP Newswire